Pharmadil

The computed 12-month bankruptcy probability of Pharmadil is 7.5% (elevated). For Pharmadil, one filing cycle of the annual accounts is missing. The 2024 annual accounts show negative equity (-€88,047) and a net result of -€69,128. Equity is shrinking by ~62% per year across the filed fiscal years. Its solvency ranks better than 8% of 9653 sector peers (fiscal year 2024). The company has been active since 2014 and the Belgian State Gazette contains no insolvency or warning signals.